In HFmrEF or HFrEF, digitalis glycosides reduce a composite of CV death or worsening HF event vs. placebo at a median 36 to 37 mo

Q: What does this research mean for the field?

Digitalis glycosides reduce a composite of cardiovascular death or worsening heart failure events compared to placebo over a median 36 to 37 months in patients with HFmrEF or HFrEF. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Dmitry Abramov; Harriette G.C. Van Spall

doi:10.7326/annals-26-03020-jc

August 31, 2026Annals of Internal Medicine

In HFmrEF or HFrEF, digitalis glycosides reduce a composite of CV death or worsening HF event vs. placebo at a median 36 to 37 mo

View at Publisher

Ask AI

Bookmark

Share

Key result

Digitalis glycosides reduce CV death or worsening heart failure vs placebo in HFmrEF and HFrEF.

Abstract

CLINICAL IMPACT RATINGS: GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Abramov et al. (2026) studied this question. Digitalis glycosides reduced a composite of cardiovascular death or worsening heart failure events compared to placebo over a median 36 to 37 months in patients with HFmrEF or HFrEF.

synapsesocial.com/papers/6a9934cf636c6408cfa7c995 https://doi.org/10.7326/annals-26-03020-jc

View at Publisher

Ask AI

Bookmark

Share

In HFmrEF or HFrEF, digitalis glycosides reduce a composite of CV death or worsening HF event vs. placebo at a median 36 to 37 mo

Abstract

Discussion

Cite This Study

In HFmrEF or HFrEF, digitalis glycosides reduce a composite of CV death or worsening HF event vs. placebo at a median 36 to 37 mo

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Annals of Internal Medicine

Keep reading

More related papers

More from Annals of Internal Medicine